Pharmaceutical Strategies Group News and Activities

Pharmaceutical Strategies Group is owned by Omnicell.

Omnicell is one of the...

• Russell 3000;
• TOB Iconic 10,000.

Omnicell is a company listed under the stock ticker OMCL (US).

They are in:

• Medical Equipment33%
• Healthcare33%
• Other33%

View the org chart displaying its 7 main executives

Most searched biographies at Pharmaceutical Strategies Group

• Michael Lonergan, President
• Mike Sackett, Senior Vice President of Financial Analytics, Procur...
• Rebekah Gregg, Chief Operating Officer

Popular executive movements at Omnicell

• Nnamdi Njoku, who was Executive Vice President, Chief Operating Officer, is promoted to President, Executive Vice President and Chief Operating Officer  (posted on July 2 2026).
• Kimberly Haught, who was Senior Manager, Talent Acquisition, is promoted to Director, Global Talent Acquisition  (posted on June 29 2026).
• Rick Couldry has joined the company as Senior Vice President and Chief Pharmacy and Clinical Officer  (posted on May 2 2026).

Click here to view some more movements at Omnicell

Create your alert
to follow the executive moves at Pharmaceutical Strategies Group.

Omnicell has 1,920 competitors including Sanofi (France), Moderna (United States (USA)) and Eli Lilly (United States (USA)).

Popular M&A news in Pharmaceuticals

• Vertex Pharmaceuticals has announced the acquisition of Crinetics Pharmaceuticals  (posted on July 7 2026).
• Novartis has announced the acquisition of Myricx Bio  (posted on July 6 2026).
• Ipsen has announced the acquisition of Kartos Therapeutics  (posted on July 3 2026).

Popular contacts in Pharmaceuticals

• David Ricks - President, Chief Executive Officer and Chairman of the Board at Eli Lilly
• Richard Saynor - Chief Executive Officer at Sandoz
• Joaquin Duato - Chief Executive Officer and Chairman of the Board at Johnson & Johnson

Learn more about the Pharmaceuticals industry

Press releases by Pharmaceutical Strategies Group

• Insights | Pharmaceutical Strategies Group
• Insights | Pharmaceutical Strategies Group
• Pharmaceutical Strategies Group | PSG | State of Specialty Spend and Trend Report Released by Pharmaceutical Strategies Group
• Pharmaceutical Strategies Group | PSG | Trends in Drug Benefit Design Report Released by Pharmaceutical Strategies Group
• Pharmaceutical Strategies Group | PSG | Amjevita, First Biosimilar of Humira, Launches With Two-Tiered Pricing Strategy
• Pharmaceutical Strategies Group | PSG | NEW PRODUCT LAUNCH: PSG Announces Artemetrx Extend
• Pharmaceutical Strategies Group | PSG | Specialty Trend Rose in 2021, but Biosimilars Are Having Impact
• Pharmaceutical Strategies Group | PSG | PSG Announces New Features Designed to Support Biosimilar Strategy
• Pharmaceutical Strategies Group | PSG | Proprietary State of Specialty Spend and Trend Report Released by Pharmaceutical Strategies Group
• Pharmaceutical Strategies Group | PSG | Trends in Drug Benefit Design Report released by Pharmaceutical Strategies Group
• View more press releases Close

Social media about Pharmaceutical Strategies Group

• Pharmaceutical Strategies Group on Wikipedia, Google News & Yahoo Finance
• Pharmaceutical Strategies Group on LinkedIn, X (Twitter) & YouTube